Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | T-cell depletion targeting CD45RA in HLA-mismatched HSCT

Mercedes Gasior Kabat • 22 Jun 2021
EHA 2021
Anemias Aplastic Anemia

Mercedes Gasior Kabat, MD, Hospital Universitario La Paz, Madrid, Spain, talks on the findings a study investigating selective T-cell depletion targeting CD45RA for patients with pediatric non-malignant hematologic diseases undergoing HLA-mismatched hematopoietic stem cell transplant. Dr Kabat reports that whilst some improvements were seen in this study, further research is required. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Mercedes Gasior Kabat

Molecular profile impacts platelet function and thrombin generation in essential thrombocythemia
4:22
Molecular profile impacts platelet function and thrombin generation in essential thrombocythemia
Mercedes Gasior Kabat • 22 Jun 2021
Donor NK cell infusion to prevent HHV6 reactivation in pediatric patients
3:13
Donor NK cell infusion to prevent HHV6 reactivation in pediatric patients
Mercedes Gasior Kabat • 1 Sep 2020
Safety and outcome of prophylactic high-dose donor CD45RO+ memory T-cells after allo-HSCT
3:06
Safety and outcome of prophylactic high-dose donor CD45RO+ memory T-cells after allo-HSCT
Mercedes Gasior Kabat • 31 Aug 2020

Related Videos

Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
1:48
Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
Ciro Rinaldi • 10 Sep 2026
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
4:29
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
Prithviraj Bose • 18 Sep 2026
Distinguishing disease- and treatment-related anemia in myelofibrosis
1:42
Distinguishing disease- and treatment-related anemia in myelofibrosis
Aaron Gerds • 21 Sep 2026
Insights into the evolving treatment paradigm for myelofibrosis beyond spleen and symptom control
1:16
Insights into the evolving treatment paradigm for myelofibrosis beyond spleen and symptom control
Haifa Kathrin Al-Ali • 13 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals